Beyond the Basics – Lower-Risk Myelodysplastic Syndromes

Saeed Sadeghi, MD, discusses the differing mechanisms of action between luspatercept and epoetin alfa, highlighting how these differences may correlate with clinical benefits for patients with lower-risk myelodysplastic syndromes (LR-MDS).

Now Viewing

EP: 1.Beyond the Basics – Lower-Risk Myelodysplastic Syndromes

Video content above is prompted by the following:

Please discuss how the mechanism of action differs between luspatercept and epoetin alfa and how it may correlate with clinical benefit for patients with LR-MDS.